William Blair Analysts Increase Earnings Estimates for WST

West Pharmaceutical Services, Inc. (NYSE:WST) – William Blair boosted their FY2025 earnings per share estimates for West Pharmaceutical Services in a report issued on Thursday, October 23rd. William Blair analyst M. Larew now expects that the medical instruments supplier will post earnings of $7.11 per share for the year, up from their prior forecast of $6.81. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. William Blair also issued estimates for West Pharmaceutical Services’ Q4 2025 earnings at $1.85 EPS, Q1 2026 earnings at $1.66 EPS, Q3 2026 earnings at $2.05 EPS and FY2026 earnings at $7.70 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. The business had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.West Pharmaceutical Services’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS.

WST has been the topic of several other reports. Barclays lifted their price target on shares of West Pharmaceutical Services from $260.00 to $275.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. KeyCorp increased their price target on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday. Rothschild & Co Redburn initiated coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They set a “buy” rating and a $311.00 price target on the stock. Finally, Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $343.56.

West Pharmaceutical Services Price Performance

Shares of WST opened at $298.13 on Monday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a twelve month low of $187.43 and a twelve month high of $348.90. The stock has a market capitalization of $21.45 billion, a P/E ratio of 44.17, a P/E/G ratio of 4.40 and a beta of 1.07. The company has a 50 day moving average of $259.30 and a 200-day moving average of $234.65.

Institutional Investors Weigh In On West Pharmaceutical Services

Several hedge funds have recently bought and sold shares of the stock. Zions Bancorporation National Association UT acquired a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $25,000. CYBER HORNET ETFs LLC acquired a new stake in West Pharmaceutical Services during the 2nd quarter worth approximately $25,000. Quarry LP bought a new stake in West Pharmaceutical Services in the 1st quarter valued at $27,000. Vermillion & White Wealth Management Group LLC grew its holdings in West Pharmaceutical Services by 193.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 95 shares in the last quarter. Finally, SJS Investment Consulting Inc. increased its position in West Pharmaceutical Services by 1,842.9% during the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 129 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.